{"name": "Biotie Therapies",
 "permalink": "biotie-therapies",
 "crunchbase_url": "http://www.crunchbase.com/company/biotie-therapies",
 "homepage_url": "http://www.biotie.com",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@biotie.com",
 "phone_number": "+358 2 274 89 00",
 "description": "",
 "created_at": "Thu Jan 13 04:13:03 UTC 2011",
 "updated_at": "Tue Jun 04 10:38:36 UTC 2013",
 "overview": "\u003Cp\u003EBiotie is a specialized drug development company focused on central nervous system and inflammatory diseases. It has several innovative small molecule and biological drug candidates at different stages of clinical development. Biotie\u0026#8217;s products address diseases with high unmet medical need and significant market potential, including addiction and a broad range of inflammatory conditions such as rheumatoid arthritis and chronic obstructive pulmonary disease (COPD). The most advanced product, nalmefene for alcohol dependence, is currently in phase III clinical development by licensing partner H. Lundbeck A/S.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       64],
      "assets/images/resized/0011/7092/117092v1-max-150x150.png"],
     [[155,
       67],
      "assets/images/resized/0011/7092/117092v1-max-250x250.png"],
     [[155,
       67],
      "assets/images/resized/0011/7092/117092v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "Chairman",
    "person":
     {"first_name": "Bradley",
      "last_name": "Bolzon",
      "permalink": "bradley-bolzon",
      "image":
       {"available_sizes":
         [[[112,
            112],
           "assets/images/resized/0025/7863/257863v1-max-150x150.jpg"],
          [[112,
            112],
           "assets/images/resized/0025/7863/257863v1-max-250x250.jpg"],
          [[112,
            112],
           "assets/images/resized/0025/7863/257863v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": false,
    "title": "President and CEO",
    "person":
     {"first_name": "Timo",
      "last_name": "Veromaa",
      "permalink": "timo-veromaa",
      "image": null}},
   {"is_past": false,
    "title": "CFO",
    "person":
     {"first_name": "Thomas",
      "last_name": "Taapken",
      "permalink": "thomas-taapken",
      "image": null}},
   {"is_past": true,
    "title": " Former Deputy Chairman and Member of Nomination \u0026 Remuneration committee",
    "person":
     {"first_name": "Bradley",
      "last_name": "Bolzon",
      "permalink": "bradley-bolzon",
      "image":
       {"available_sizes":
         [[[112,
            112],
           "assets/images/resized/0025/7863/257863v1-max-150x150.jpg"],
          [[112,
            112],
           "assets/images/resized/0025/7863/257863v1-max-250x250.jpg"],
          [[112,
            112],
           "assets/images/resized/0025/7863/257863v1-max-450x450.jpg"]],
        "attribution": ""}}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$0",
 "funding_rounds":
  [],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [{"price_amount": 121500000.0,
    "price_currency_code": "USD",
    "term_code": null,
    "source_url": "http://www.fiercebiotech.com/story/biotie-buys-cns-developer-synosia-1215m-deal/2011-01-11?utm_medium=rss\u0026utm_source=rss",
    "source_description": "Biotie buys CNS developer Synosia in $121.5M deal  Read more: Biotie buys CNS developer Synosia in $121.5M deal - FierceBiotech http://www.fiercebiotech.com/story/biotie-buys-cns-developer-synosia-1215m-deal/2011-01-11?utm_medium=rss\u0026utm_source=rss#ixzz1A",
    "acquired_year": 2011,
    "acquired_month": 1,
    "acquired_day": 11,
    "company":
     {"name": "Synosia Therapeutics",
      "permalink": "synosia-therapeutics",
      "image":
       {"available_sizes":
         [[[150,
            49],
           "assets/images/resized/0004/3264/43264v1-max-150x150.png"],
          [[217,
            71],
           "assets/images/resized/0004/3264/43264v1-max-250x250.png"],
          [[217,
            71],
           "assets/images/resized/0004/3264/43264v1-max-450x450.png"]],
        "attribution": null}}},
   {"price_amount": null,
    "price_currency_code": "USD",
    "term_code": null,
    "source_url": "http://www.sys-con.com/node/2684559",
    "source_description": "Biotie Purchases Option to Acquire Neurelis, Inc. ",
    "acquired_year": 2013,
    "acquired_month": 6,
    "acquired_day": 4,
    "company":
     {"name": "Neurelis",
      "permalink": "neurelis",
      "image": null}}],
 "offices":
  [{"description": "",
    "address1": "Tykist\u00c3\u00b6katu 6",
    "address2": "",
    "zip_code": "FI-20520",
    "city": "Turk",
    "state_code": null,
    "country_code": "FIN",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}